Traws Pharma, Inc. (TRAW) stock
Close on Nov 11, 2026Market cap $3.84MP/E –Yield –
Traws Pharma, Inc. grew revenue 1134.5% to $2.79M over fiscal 2025. Free cash flow was -$20.77M. At the latest close the market valued the company at $3.84M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $3.84M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $2.79M
- Net income
- -$21.57M
- EPS, diluted
- $0.82
- Free cash flow
- -$20.77M
- Diluted shares
- 16M
Trading
- Next earnings
- Nov 12, 2026 (estimated, before the open)
- Previous close
- $0.23
- Open
- $0.23
- Day's range
- $0.23 – $0.26
- Volume
- 150,589
- Average volume (20 days)
- 146,052
- Beta (5 years)
- 1.18
- 52-week range
- $0.22 – $3.23
- RSI (14 days)
- 31.1
- Volatility (1 year)
- 128.5%
- Relative volume
- 0.33×
- WACC
- 10.8%
Market cap history
Month-end market cap since 2013, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | TRAW | S&P 500 | Difference | TRAW per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -43.8% | -2.4% | −41.4 pts | ||
| 3 months | -53.8% | -1.2% | −52.6 pts | ||
| Year to date | -77.9% | +12.3% | −90.2 pts | ||
| 1 year | -86.8% | +12.4% | −99.2 pts | ||
| 3 years | -98.4% | +78.8% | −177.2 pts | -75.0% | +21.4% |
| 5 years | -99.7% | +75.2% | −174.9 pts | -69.0% | +11.9% |
| 10 years | -100.0% | +311.1% | −411.1 pts | -66.8% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Traws Pharma filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Update
- Update
- Update
- Results
About Traws Pharma
Pharmaceutical Preparations
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for respiratory viral diseases and cancers. The company's lead infectious disease programs include tivoxavir marboxil, an oral cap-dependent endonuclease inhibitor evaluated for avian and seasonal influenza, and ratutrelvir, a main protease inhibitor investigated for COVID-19 treatment. Its oncology assets comprise narazaciclib, a multi-targeted kinase inhibitor targeting cyclin-dependent kinases for solid tumors and hematological cancers, and rigosertib, a polo-like kinase 1 inhibitor evaluated in rare skin cancers and RASopathy-related conditions. As a development-stage enterprise, Traws Pharma does not sell commercial products directly to consumers; its activities center on advancing investigational treatments through clinical trials and collaborating with biopharmaceutical partners and government agencies.
Company profile, executives and historyTraws Pharma stock: common questions
What is Traws Pharma's stock price?
TRAW closed at $0.25 on Nov 11, 2026, up 11.11% on the day. Over the past 52 weeks it traded between $0.22 and $3.23.
What is Traws Pharma's market cap?
Traws Pharma was worth $3.84M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
How much revenue does Traws Pharma make?
Traws Pharma reported revenue of $2.79M for fiscal 2025, up 1134.5% from a year earlier.
Does Traws Pharma pay a dividend?
No. Traws Pharma has not paid a cash dividend over the last twelve months.
When does Traws Pharma report earnings next?
Traws Pharma is expected to report Q3 FY2026 results on Nov 12, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has TRAW stock performed over the past year?
Including dividends, TRAW returned -86.8% over the past year, against +12.4% for the S&P 500.
How many TRAW shares are sold short?
1M shares were sold short at the latest FINRA report, 6.92% of the float, or 4.1 days of average trading volume.
Who are Traws Pharma's competitors?
Companies most similar to Traws Pharma by business, industry and size include TVRD, CNTB, UPB, XBIO, IMNM.
See a number that looks wrong?